公开(公告)号：US10722519B2

公开(公告)日：2020-07-28

申请号：US16194954

申请日：2018-11-19

Applicant: Horizon Orphan LLC

Inventor： David C. Griffith ,  Michael N. Dudley ,  Mark W. Surber ,  Keith A. Bostian ,  Olga Rodny

IPC: A61K31/397 ,  A61K31/535 ,  A61P11/06 ,  A61K31/5383 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/538 ,  A61K47/02 ,  A61K9/00 ,  A61K31/536

Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

公开(公告)号：US10149854B2

公开(公告)日：2018-12-11

申请号：US15635818

申请日：2017-06-28

Applicant: Horizon Orphan LLC

Inventor： David C. Griffith ,  Michael N. Dudley ,  Mark W. Surber ,  Keith A. Bostian ,  Olga Rodny

IPC: A61K31/397 ,  A61K31/535 ,  A61P11/06 ,  A61K31/5383 ,  A61K9/00 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/538 ,  A61K47/02 ,  A61K31/536

Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

公开(公告)号：US20180104252A1

公开(公告)日：2018-04-19

申请号：US15635818

申请日：2017-06-28

Applicant: Horizon Orphan LLC

Inventor： David C. Griffith ,  Michael N. Dudley ,  Mark W. Surber ,  Keith A. Bostian ,  Olga Rodny

IPC: A61K31/5383 ,  A61K31/536 ,  A61K9/00 ,  A61K31/538 ,  A61K31/47 ,  A61K31/4375 ,  A61K47/02

CPC classification number: A61K31/5383 ,  A61K9/0073 ,  A61K9/0078 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/536 ,  A61K31/538 ,  A61K47/02 ,  Y02A50/401 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/47 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481 ,  Y02A50/483

Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

公开(公告)号：US10987357B2

公开(公告)日：2021-04-27

申请号：US16250520

申请日：2019-01-17

Applicant: Horizon Orphan, LLC

Inventor： Mark W. Surber ,  Keith A. Bostian ,  Michael N. Dudley ,  Olga Rodny ,  David C. Griffith

IPC: A61K31/5383 ,  A61K47/02 ,  A61K9/00 ,  A61K9/51

Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.